In addition to the combination of the varied business and economic factors impacting the addiction treatment field, the manner in which insurance companies and the government view addiction treatment is also changing.
As a result, more than any other, abstinence-based providers stand to be disempowered by the movement toward pay-for-value models.
Medication Assisted Treatment (MAT), which involves medication as an adjunct to therapy has been buttressed by the dozens of safety and efficacy trials required by the FDA for drug approval.
The data behind MAT is therefore much stronger than the data supporting any other approach to treatment. Insurance companies and investment groups will require demonstrable validation of efficacy rates.
In 2016, U.S. Surgeon General, Dr. Vivek Murthy, plans to release a report on substance use, addiction and health, the first of its kind to be released by a Surgeon General.
His report will largely establish MAT as the clinical backbone of opioid treatment.
As a strategy, insurance companies are seeking quality MAT programs to fill the ranks of their networks and to be the ‘go-to’ facilities for their members. Government and commercial insurance companies have begun to pivot away from abstinence-only providers as the solution to treating many who suffer from addiction and a small and growing contingent of abstinence-based providers recognize this substantial shift.
On the surface, future prospects for many commercially reimbursed, abstinence only addiction treatment providers may seem gloomy and wrought with existential issues. It stands to reason that some providers may not be able to navigate the evolving landscape however many providers have embraced the change.
Treatment providers who were previously unconcerned and disinterested recognize the critical need to demonstrate treatment outcomes, to embrace technology platforms to improve clinical services and to some degree engage insurance companies.
Computer-based technology has a rewarding history in healthcare, although the Behavioral Health space, especially addiction treatment, has largely eluded its influence. However, with the advances in Electronic Medical Record (EMR) technology and the advent of sophisticated platforms for outcomes data collection and demonstration, this is changing.
There are many positive implications associated with the utilization of technology in this field and while in its relative infancy, the potential benefits are widespread.
Much like the field of Oncology and other evidenced-based models, the field of addiction treatment will be well-served to be empowered with state-of-the art technology platforms in order to reach the millions of Americans who are going without treatment.
Telehealth is proving to be successful in other segments of healthcare and is on the horizon to constructively transform the provision of addiction treatment. Healthcare reimbursements are declining although telehealth has proven to be a bright spot and resides at the beginning of a considerable growth curve.
Google and other major corporations have made significant investments in telehealth and other healthcare technology platforms.
In concordance with the progress toward technology, the addiction treatment field is sitting on the cusp of embracing data as a method to improve its clinical outcomes.
With the advent of MAT and the collection of outcomes data, providers will be better informed as to their rates of efficacy and success which will result in improved treatment protocols and the alignment of patients with the treatment provider best-suited for their particular disease state.
The collection and demonstration of outcomes data will drive the manner in which health insurance companies’ contract with providers. As in other segments of healthcare, a value-for-performance aptitude is imminent.
The field of Behavioral Health is in transition. With the advent of MAT, EMR and breakthrough technology applications, addiction treatment providers have the opportunity to collect outcomes data that demonstrate their success rates to health insurance companies who are adapting to pay-for-performance models.
The interests and agendas of investment groups will insure the field will continue to be consolidated and corporatized.
Without the capacity to demonstrate long-term positive outcomes and embracing technology and data, it is likely that programs will become antiquated as the increasingly savvy consumer will seek treatment based on demonstrated rates of efficacy.
In this regard, abstinence-based programs may be particularly vulnerable. These changes, while intimidating to some, will ultimately distinguish treatment providers to insurance companies and potential patients and further validate and recognize the field of addiction treatment.
,  https://www.drugabuse.gov/publications/drugfacts/nationwide-trends
Data concept image available from Shutterstock